Arun K. Ghosh

Prof. Dr. Arun K. Ghosh

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AGArun K. Ghosh
Arun K. Ghosh
Margherita BrindisiMargherita Brindisi
Margherita Brindisi
The carbamate group is a key structural motif in many approved drugs and prodrugs. There is an increasing use of carbamates in medicinal chemistry and many derivatives are specifically designed to make drug–target interactions through their carbamate moiety. In this Perspective, we present properties and stabilities of carbamates, reagents and chemical methodologies for the synthesis of carbamates, and recent applications of carbamates in drug design and medicinal chemistry.

21 October 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KRKiira Ratia
Kiira Ratia
SPScott Pegan
Scott Pegan
JTJun Takayama
Jun Takayama
KSKatrina Sleeman
Katrina Sleeman
MCMelissa Coughlin
Melissa Coughlin
AMAndrew D. David Mesecar
Andrew D. David Mesecar
We report the discovery and optimization of a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). This unique protease is not only responsible for processing the viral polyprotein into its functional units but is also capable of cleaving ubiquitin and ISG15 conjugates and plays a significant role in helping SARS-CoV evade the human immune system. We screened a structurally diverse library of 50,080 compounds for inhibitors of PLpro and discovered a noncovalent lead inhibitor with an IC 50 value of 20 μM, which was improved to 600 nM via synthetic optimization. The resulting compound, GRL0617, inhibited SARS-CoV viral replication in Vero E6 cells with an EC 50 of 15 μM and had no associated cytotoxicity. The X-ray structure of PLpro in complex with GRL0617 indicates that the compound has a unique mode of inhibition whereby it binds within the S4-S3 subsites of the enzyme and induces a loop closure that shuts down catalysis at the active site. These findings provide proof-of-principle that PLpro is a viable target for development of antivirals directed against SARS-CoV, and that potent noncovalent cysteine protease inhibitors can be developed with specificity directed toward pathogenic deubiquitinating enzymes without inhibiting host DUBs.

22 January 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGArun K. Ghosh
Arun K. Ghosh
HOHeather L. Osswald
Heather L. Osswald
GPGary Prato
Gary Prato

2 December 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGArun K. Ghosh
Arun K. Ghosh
Margherita BrindisiMargherita Brindisi
Margherita Brindisi

7 May 2020 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
AGArun K. Ghosh
Arun K. Ghosh
MBMargherita Brindisi
Margherita Brindisi
DSDana Shahabi
Dana Shahabi
MCMackenzie E. Chapman
Mackenzie E. Chapman
AMAndrew D. Mesecar
Andrew D. Mesecar

28 August 2007 in Accounts of Chemical Research
Verified
Journal Article
Closed access
AGArun K. Ghosh
Arun K. Ghosh
BCBruno D. Chapsal
Bruno D. Chapsal
IWIrene T. Weber
Irene T. Weber
HMHiroaki Mitsuya
Hiroaki Mitsuya